Ibrance Offers No More Benefits Than Other Breast Cancer Treatments, Analysis Says

Ibrance Offers No More Benefits Than Other Breast Cancer Treatments, Analysis Says
The breast cancer therapy Ibrance (palbociclib) offers no more benefits than treatments with which it was compared in clinical trials, according to an analysis by the German Institute for Quality and Efficiency in Health Care. In addition, the institute’s dossier assessment, which covers a new therapy's benefits once it reaches the market, concluded that data was inadequate or even missing for several treatment groups, including those receiving Ibrance as a second-line therapy. That makes an accurate assessment impossible, the institute said. Ibrance is approved in the United States and Europe for women with HR-positive, HER2-negative locally advanced or metastatic breast cancer. The approvals are for a combination of Ibrance and either an aromatase inhibitor or Faslodex (fulvestrant) in women who received endocrine -- or hormone -- therapy earlier. In examining possible benefits of the treatment, institute researchers looked at different patient groups, including both premenopausal and postmenopausal women, and women with previous treatments that were unsuccessful. Pfizer, which manufactures Ibrance, had conducted two randomized clinical trials in postmenopausal women, who took it as a first-line treatment. The trials compared a combination of Ibrance and Femara (letrozole) with the use of Femara alone. Researchers found no differences in benefits between the two groups when they compared the women's health status, health-related quality of life, and discontinuation of treatment due to side e
Subscribe or to access all post and page content.